Get the Stockscreener App
1.0695
1.74%
-0.0105
Atai Life Sciences N V stock is traded at $1.0695, with a volume of 459.13K.
It is down -1.74% in the last 24 hours and down -8.52% over the past month.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
See More
Previous Close:
$1.08
Open:
$1.1
24h Volume:
459.13K
Relative Volume:
0.76
Market Cap:
$182.90M
Revenue:
$314.00K
Net Income/Loss:
$-40.23M
P/E Ratio:
-1.1625
EPS:
-0.92
Net Cash Flow:
$-84.71M
1W Performance:
-6.91%
1M Performance:
-8.52%
6M Performance:
-48.23%
1Y Performance:
-19.61%
1-Day Range:
$1.05
$1.12
1-Week Range:
$1.04
$1.1757
52-Week Range:
$1.025
$2.85
Atai Life Sciences N V Stock (ATAI) Company Profile
Name
Atai Life Sciences N V
Sector
Industry
Phone
(617)-699-5876
Address
WALLSTRASSE 16, BERLIN
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Atai Life Sciences N V Stock (ATAI) Latest News
Are ATAI Life Sciences N.V.’shares a good deal? - US Post News
Insider Sale Alert: ATAI Life Sciences N.V. [ATAI] – Is it Time to sell? - Knox Daily
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit - StockTitan
Selling Buzz: ATAI Life Sciences N.V. [ATAI] 10% Owner ATAI Life Sciences N.V. sells 2,660,000 shares of the company - Knox Daily
ATAI Life Sciences N.V. (ATAI)’s results reveal risk - US Post News
Maxim Group gives a Buy recommendation for ATAI Life Sciences N.V. (ATAI) - Knox Daily
ATAI Life Sciences completes acquisition of IntelGenx Corp. - Investing.com India
ATAI Life Sciences completes acquisition of IntelGenx Corp. By Investing.com - Investing.com South Africa
10% Owner ATAI Life Sciences N.V. sale 2,660,000 shares of ATAI Life Sciences N.V. [ATAI] - Knox Daily
ATAI Life Sciences N.V. (ATAI) stock analysis: A comprehensive overview - US Post News
Trading Day Review: ATAI Life Sciences N.V. (ATAI) Loses Momentum, Closing at 1.16 - The Dwinnex
A History of Outperforming Analyst Forecasts and Beating the Odds: ATAI Life Sciences N.V. (ATAI) - SETE News
Maxim Group Upgrades ATAI Life Sciences N.V. (ATAI) to a Buy from a Hold - Knox Daily
Life Sciences N.V. Atai Sells 2,660,000 Shares of COMPASS Pathways plc (NASDAQ:CMPS) Stock - MarketBeat
Atai Life Sciences executives sell shares valued at $16 million - Investing.com India
Deeper Dive: Understanding ATAI Life Sciences N.V. (ATAI) Through its Various Ratios - The Dwinnex
ATAI Life Sciences N.V. (ATAI) deserves closer scrutiny - US Post News
ATAI Life Sciences N.V. [ATAI] Shares Fall Approximately -7.81% Over the Year - Knox Daily
TWKS SPECIAL ALERT: Thoughtworks Shareholders Seeking More Than $4.40 Per Share Contact Julie & Holleman Regarding Sale to Apax - PR Newswire
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
T2 Biosystems Achieves Successful Defense of Patent for - GlobeNewswire
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology - StockTitan
Magic mushroom market set to go gangbusters, Irish researcher says - Mugglehead
ATAT’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter
Australian Clinical Labs Shareholder Stake Shifts - TipRanks
(ATAT) Trading Advice - Stock Traders Daily
T2 Biosystems director sells shares worth $133 - Investing.com India
Atour Lifestyle Holdings Ltd ADR (ATAT) is looking forward to a strong quarter - SETE News
Atour Lifestyle Holdings Limited (NASDAQ:ATAT) Short Interest Down 8.3% in August - MarketBeat
Alzheimer’s drug developer Actinogen rattles the tin - The Australian Financial Review
Substantial Stake Acquired in Australian Clinical Labs - TipRanks
Cat defies the odds to survive after being born with two faces - MSN
ATAI Life Sciences N.V. [ATAI] See Remarks makes an insider sale of 151,303 shares worth $0.29 million. - Knox Daily
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients - GlobeNewswire
Two-faced kitten in Phetchabun leaves locals feline lottery curious - Thaiger
Monitoring ATAI Life Sciences N.V. (ATAI) after recent insider movements - Knox Daily
Market Watch Highlights: ATAI Life Sciences N.V. (ATAI) Ends on an Upturn Note at 1.24 - The Dwinnex
ATAI Life Sciences N.V. [ATAI] Insider Activity: An Update for Investors - Knox Daily
ATAI Life Sciences N.V. (ATAI)’s stock chart: A technical perspective - US Post News
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Psychedelic Drugs Market to Grow by USD 1.37 Billion from 2024-2028, Driven by Increasing Mental Health Disorders, Report Highlights AI's Impact on the Market LandscapeTechnavio - The Malaysian Reserve
Psychedelic Stock Deep Dive: Atai Life Sciences (ATAI) (NASDAQ:ATAI) - Seeking Alpha
H.C. Wainwright raises outlook on atai Life Sciences stock as pipeline progresses - Investing.com
Market Momentum: ATAI Life Sciences N.V. (ATAI) Registers a -1.56 Decrease, Closing at 1.26 - The Dwinnex
ATAI Life Sciences N.V. (ATAI) presents a great opportunity, but the stock is slightly undervalued - US Post News
ATAI Life Sciences N.V. (ATAI) may enjoy gains as insiders got busy in the recent days - Knox Daily
ATAI Life Sciences N.V. [NASDAQ: ATAI] Sees Decrease in Stock Value - Knox Daily
Can you still get a good price for ATAI Life Sciences N.V. (ATAI) Shares at this point? - US Post News
Analyzing ATAI Life Sciences N.V. (ATAI) After Recent Trading Activity - Knox Daily
Atai Life Sciences N V Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):